| # | Title | Journal | Year | Citations |
|---|
| 1 | Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2015 | 5,183 |
| 2 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1,749 |
| 3 | Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer | Nature Medicine | 2018 | 1,071 |
| 4 | Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer | Nature Communications | 2017 | 743 |
| 5 | Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer | Nature Medicine | 2013 | 634 |
| 6 | Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study | Journal of Clinical Oncology | 2006 | 560 |
| 7 | Gastric adenocarcinoma | Nature Reviews Disease Primers | 2017 | 409 |
| 8 | Progression of Monoclonal Gammopathy with Undetermined Significance to Multiple Myeloma Diagnosed by Kidney Biopsy: A Case Report | Case Reports in Nephrology and Dialysis | 2015 | 375 |
| 9 | SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group | Blood | 2012 | 361 |
| 10 | Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project | Clinical Cancer Research | 2017 | 342 |
| 11 | The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma | Blood | 2007 | 283 |
| 12 | A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) | Annals of Oncology | 2015 | 275 |
| 13 | Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma | Cancer Discovery | 2018 | 248 |
| 14 | Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype | Nature Communications | 2018 | 245 |
| 15 | Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) | Annals of Oncology | 2019 | 230 |
| 16 | Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study | European Journal of Cancer | 2013 | 218 |
| 17 | Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer | Journal of Thoracic Oncology | 2018 | 203 |
| 18 | Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC | Journal of Hepatology | 2017 | 178 |
| 19 | Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial | Lancet, The | 2021 | 177 |
| 20 | Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2007 | 175 |
| 21 | Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2015 | 172 |
| 22 | Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data | Genome Research | 2018 | 172 |
| 23 | Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing | Nature Communications | 2014 | 166 |
| 24 | Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors | Journal of Thoracic Oncology | 2013 | 163 |
| 25 | Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non–Small-Cell Lung Cancer | Journal of Thoracic Oncology | 2015 | 163 |
| 26 | Host Inflammatory Response Predicts Survival of Patients With Epstein-Barr Virus–Associated Gastric Carcinoma | Gastroenterology | 2010 | 162 |
| 27 | Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients | British Journal of Cancer | 2009 | 159 |
| 28 | Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma | Hepatology | 2013 | 159 |
| 29 | Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study | Lancet Oncology, The | 2021 | 157 |
| 30 | EGFR TKI combination with immunotherapy in non-small cell lung cancer | Expert Opinion on Drug Safety | 2017 | 156 |
| 31 | Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial | Journal of Thoracic Oncology | 2021 | 156 |
| 32 | Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial | Cancer Discovery | 2019 | 155 |
| 33 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Gastric Cancer | 2020 | 155 |
| 34 | A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆ | Annals of Oncology | 2021 | 153 |
| 35 | Extranodal nasal type NK/T-cell Lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy | European Journal of Cancer | 2005 | 152 |
| 36 | Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications | Annals of Surgical Oncology | 2010 | 147 |
| 37 | Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer | Journal of Thoracic Oncology | 2009 | 145 |
| 38 | Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy | Nature Genetics | 2018 | 145 |
| 39 | Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma | Clinical Cancer Research | 2019 | 142 |
| 40 | Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome | Annals of Hematology | 2007 | 137 |
| 41 | Lung adenocarcinoma promotion by air pollutants | Nature | 2023 | 135 |
| 42 | Type II enteropathy‐associated T‐cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group | American Journal of Hematology | 2012 | 134 |
| 43 | Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) | Oncotarget | 2016 | 134 |
| 44 | Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study | Biology of Blood and Marrow Transplantation | 2008 | 133 |
| 45 | ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation | British Journal of Cancer | 2008 | 132 |
| 46 | Chemotherapy for pulmonary large cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer? | Lung Cancer | 2012 | 130 |
| 47 | Prediction of Disease-free Survival in Hepatocellular Carcinoma by Gene Expression Profiling | Annals of Surgical Oncology | 2013 | 130 |
| 48 | Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice | Nature Microbiology | 2021 | 130 |
| 49 | ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer | Gastroenterology | 2016 | 127 |
| 50 | Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy | Molecular Cancer Therapeutics | 2011 | 126 |
